Research grogress in the application of C5b-9 in complement-associated renal disease
C5b-9,the end product of complement activation,plays an important role in the pathogenesis of several renal diseases.C5b-9 mediates renal injury by depositing in different forms in glomerular capillary walls,tubules,tunica albuginea,and other structures,and correlates with the severity of tissue damage and disease activity.Inhibiting the formation of C5b-9 can alleviate clinical symptoms such as proteinuria.Currently,the C5 inhibitor Eculizumab has been used in the clinic,and it has achieved remarkable results in some patients by reducing the deposition of C5b-9 in the kidney,reducing renal tissue damage,and improving renal function.Enhancing the understanding of C5b-9 will provide new ideas for the diagnosis and treatment of complement-associated renal diseases.This article summarizes the roles played by C5b-9 in various renal diseases and possible therapeutic targets.
NETL
NSTL
万方数据
